SNWV

Business Context and Reporting Period

Company: SANUWAVE Health, Inc. (SNWV)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Sanuwave is a medical device company focused on regenerative medicine using directed energy (ultrasound and shockwaves) for wound care. Its primary products are the UltraMIST® system (non-contact ultrasound) and the PACE® family (acoustic shockwaves). The company operates as a single reporting segment and is headquartered in Eden Prairie, Minnesota.

Key Financial Metrics

Note: Net loss includes a non-cash charge of $31.4 million related to the change in fair value of derivative liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 60% to $32.6 million, driven by a 77% increase in UltraMIST system sales and a 37% increase in consumable sales. UltraMIST products accounted for 98% of total revenue.
• Operating Profitability: The company achieved operating income of $5.4 million in 2024, a turnaround from an operating loss of $0.5 million in 2023. This was driven by revenue growth and improved gross margins (75% vs. 70%).
• Net Loss Increase: Despite operating income, the net loss widened to $31.4 million due to a $21.8 million increase in the loss from the change in fair value of derivative liabilities, partially offset by a $6.3 million gain on debt extinguishment.
• Capital Structure: The company completed a 1:375 reverse stock split in October 2024. It also converted outstanding convertible notes and warrants into common stock and raised approximately $10.3 million in a private placement.
• Cash Flow: Operating cash flow turned positive ($2.5 million) compared to a negative $4.5 million in 2023, attributed to improved cash management and operating expense controls.

Guidance, Outlook, Risks, and Contingencies

• Going Concern: The filing raises substantial doubt about the company's ability to continue as a going concern for 12 months due to recurring losses, negative working capital, and a Senior Secured Note due in September 2025. Management is actively seeking refinancing.
• Internal Controls: The company identified material weaknesses in internal control over financial reporting, specifically regarding the application of U.S. GAAP to complex financial instruments and a lack of controls in key accounting processes. These were not remediated as of December 31, 2024.
• Outlook: Management expects to continue focusing on profitable growth and commercialization of UltraMIST. The company plans to raise additional capital in 2025 to fund operations and refinance debt.
• Recent Developments: Trading on the Nasdaq Global Market commenced on March 7, 2025, under the ticker "SNWV."
• Risks: Key risks include dependency on third-party payors for reimbursement, supply chain concentration (single suppliers for key components), and the need for additional financing to meet debt obligations.

Investor Verification Checklist

• Debt Refinancing Status: Verify the progress of discussions to refinance the $25.3 million Senior Secured Note due in September 2025.
• Internal Control Remediation: Monitor the timeline and effectiveness of the plan to remediate material weaknesses in financial reporting controls.
• Derivative Liability Volatility: Assess the impact of warrant and derivative valuations on future net income, as these non-cash charges significantly distort GAAP profitability.
• Reimbursement Stability: Confirm the stability of CMS reimbursement codes (97610) for UltraMIST, which drives the majority of revenue.
• Liquidity Runway: Evaluate the sufficiency of the $10.2 million cash balance against operating burn rates and upcoming debt maturities.